Pot-Kast: Thrombosis Prophylaxis After Knee Arthroscopy

NCT ID: NCT01542723

Last Updated: 2016-10-11

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: NA
• Total Enrollment: 1500 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2012-05-31
• Study Completion Date: 2016-09-30

Brief Summary

Currently, guidelines and clinical practice differ considerably with respect to use of anticoagulant treatment after arthroscopy of the knee. Trials that have been carried out were aimed at efficacy only, had small sample sizes and therefore mainly used asymptomatic thrombosis as endpoint. From these trials an overall risk benefit-balance could not be established, hence the current controversy. In the proposed study the investigators will use relevant symptomatic endpoints in a large cohort of patients. Furthermore the investigators will follow subjects with an adverse event for a longer period, during which the investigators will assess the long term sequelae of these events. Lastly, the investigators will determine high risk groups that will benefit most from anticoagulant treatment.

Objective: Comparative effectiveness research to determine cost-effectiveness of two existing policies, i.e. treatment with low molecular weight heparin (LMWH) after arthroscopy of the knee. In addition the investigators will investigate personalized prophylaxis based on genetic and acquired risk factors.

Detailed Description

Background:

Currently, guidelines and clinical practice differ considerably with respect to use of anticoagulant treatment after arthroscopy of the knee. Trials that have been carried out were aimed at efficacy only, had small sample sizes and therefore mainly used asymptomatic thrombosis as endpoint. From these trials an overall risk benefit-balance could not be established, hence the current controversy exists. In the proposed study we will use relevant symptomatic endpoints in a large cohort of patients. Furthermore we will follow subjects with an adverse event for a longer period, during which we will assess the long term sequelae of these events. Lastly, we will determine high risk groups that will benefit most from anticoagulant treatment.

Objective:

Comparative effectiveness research to determine cost-effectiveness of an existing healthcare policy, i.e. treatment with low molecular weight heparin (LMWH) after arthroscopy of the knee. In addition we will investigate personalized prophylaxis based on genetic and acquired risk factors.

Study Design:

A randomized controlled trial comparing a policy with the anticoagulant LMWH to a policy with no anticoagulant in patients who underwent knee arthroscopy.

Determination of genetic and acquired risk factors will be performed at the start of the study. Based on the presence or absence of these factors we will assign a risk profile to each patient

Study Population:

The study population will consist of 1500 patients undergoing knee arthroscopy. These patients will be recruited from 6 hospitals in the Leiden/Den Haag region over a two-year inclusion period. All patients over 18 years will be eligible, except patients with a contra-indication or an absolute indication for LMWH use

Intervention:

LMWH (for example nadroparin 2850 IE s.c. once daily, > 100kg 5700IE sc) for 8 days vs no treatment.

Each hospital will use a LMWH according to their own preference.

Blood taken pre- and post-operatively will be analyzed on common single nucleotide polymorphisms (SNPs) known to strongly affect thrombotic risk; on levels of coagulation factors in plasma (of which high or low levels are known to increase the risk). Patients will also be screened on acquired risk factors for thrombosis through a questionnaire.

Nature and extent of the burden and risks associated with participation, benefit and group relatedness:

We will compare two standard treatment modes that are currently both used depending on the physician's or hospital's preference. The patients in our trial will be subjected to one of these standard treatments. It is therefore not expected that participation will lead to an increased health risk. LMWHs like Nadroparin and Dalteparin are no experimental pharmaceuticals; both have been registered in the Netherlands for these indications since 1989.

Not participating in the trial may, depending on the physician, still lead to treatment with an LMWH.

All patients will need to undergo two venepunctures for blood sampling for the study. These blood samples will be taken pre-operatively and post-operatively. No extra hospital visits are required. Patients will be contacted by an electronic questionnaire 2 weeks and 6 weeks after the arthroscopy of the knee and by telephone after three months.

One questionnaire concerning risk factors for thrombosis, bleeding and patients demographics will be filled in before arthroscopy of the knee.

Only subjects with clinically relevant adverse events (and a similar random sample of subjects without a clinically relevant adverse event) will be monitored for a two year period after the event (in total expected to be about 30 subjects). After six months, one year and two years after the event, patients will be seen for clinical examination and quality of life assessment by means of a questionnaire.

Conditions

Deep Venous Thrombosis; Pulmonary Embolism

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: PREVENTION
• Blinding Strategy: NONE

Study Groups

LMWH

750 patients with an arthroscopy or the knee will be randomized to receive treatment with a LMWH

Group Type: EXPERIMENTAL

LMWH

Intervention Type: DRUG

Each hospital will use a LMWH according to their own preferences.

Prophylactic dosage of LMWH (for example nadroparin 2850 IE s.c.) once daily for 8 days. If the patient's weight is more than 100kg a double dose of LMWH will be given (in case of Nadroparin 5700 IE s.c. once daily).

No intervention

750 patients with an arthroscopy of the knee will be randomized to receive no treatment.

Group Type: NO_INTERVENTION

No interventions assigned to this group

Interventions

LMWH

Each hospital will use a LMWH according to their own preferences.

Prophylactic dosage of LMWH (for example nadroparin 2850 IE s.c.) once daily for 8 days. If the patient's weight is more than 100kg a double dose of LMWH will be given (in case of Nadroparin 5700 IE s.c. once daily).

Intervention Type: DRUG

Other Intervention Names

Nadroparine; Dalteparine

Eligibility Criteria

Inclusion Criteria

• Meniscectomy
• Diagnostic Arthroscopy
• Removal of corpora libera

Exclusion Criteria

• Contra-indications for LMWH use (recent major bleeding, bleeding disorder, allergy)
• Pregnancy
• Pre-existent indication for anticoagulation therapy, either LMWH or vitamin K antagonists.
• History of venous thromboembolism (indication for anticoagulation therapy for prophylaxis of recurrence)
• Mental of physical disability to fulfill study requirements
• Insufficient knowledge of the Dutch language
• Previous participation in the Pot-(K)Cast study

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

ZonMw: The Netherlands Organisation for Health Research and Development

OTHER

Sponsor Role: collaborator

Suzanne C. Cannegieter, MD PhD

OTHER

Sponsor Role: lead

Responsible Party

Suzanne C. Cannegieter, MD PhD

Study director

Responsibility Role: SPONSOR_INVESTIGATOR

Principal Investigators

Suzanne C Cannegieter, PhD, MD

Role: STUDY_DIRECTOR

Leiden University Medical Center

Rob GHH Nelissen, PhD, MD

Role: PRINCIPAL_INVESTIGATOR

Leiden University Medical Center

Locations

Isala Klinieken

Zwolle, Overijsel, Netherlands

Orthopedium

Delft, South Holland, Netherlands

Reinier de Graaf Groep

Delft, South Holland, Netherlands

Groene Hart Ziekenhuis

Gouda, South Holland, Netherlands

Leiden University Medical Center

Leiden, South Holland, Netherlands

Alrijne Ziekenhuis

Leiderdorp, South Holland, Netherlands

PARK MC

Rotterdam, South Holland, Netherlands

Medisch Centrum Haaglanden

The Hague, South Holland, Netherlands

HagaZiekenhuis

The Hague, South Holland, Netherlands

Countries

Netherlands

References

van Adrichem RA, Nemeth B, Algra A, le Cessie S, Rosendaal FR, Schipper IB, Nelissen RGHH, Cannegieter SC; POT-KAST and POT-CAST Group. Thromboprophylaxis after Knee Arthroscopy and Lower-Leg Casting. N Engl J Med. 2017 Feb 9;376(6):515-525. doi: 10.1056/NEJMoa1613303. Epub 2016 Dec 3.

Reference Type: DERIVED

PMID: 27959702 (View on PubMed)

Other Identifiers

NL35774.058.11(2)

Identifier Type: -

Identifier Source: org_study_id